The study has been designed to assess the effect of cyclooxygenase inhibition on blood pressure, cerebral blood flow, ventilation and renal hemodynamics following chronic intermittent hypoxia exposure.
The study will specifically evaluate: 1. Cardiovascular effect of cyclooxygenase inhibitors on cerebral, vascular, blood pressure and homeostatic responses following chronic intermittent hypoxia exposure. 2. Ventilatory response of cyclooxygenase inhibitors following chronic intermittent hypoxia exposure 3. Evaluate the renal hemodynamic effect of chronic intermittent hypoxia exposure and cyclooxygenase inhibition.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
12
The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia. Indomethacin: 50 mg, Oral, three times per day for five days.
The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia. Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.
The Laboratory of Human Cerebrovascular Physiology, HMRB 209 & HMRB 230, University of Calgary
Calgary, Alberta, Canada
Arterial Blood Pressure
Blood pressure will be monitored during all three protocols.
Time frame: Six weeks
Cerebral Blood Flow
The cerebral blood flow will be mesauresed during each testing days of all three protocols.
Time frame: Six weeks
Ventilatory Response
The ventilatory response will be measured during each testing days of all three protocols.
Time frame: Six weeks.
Renal Hemodynamics
The renal hemodynamics will be measured during each testing days of all three protocols.
Time frame: Six weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia. Placebo: Oral, three times per day for five days.